Sonoma BioTherapeutics develops adoptive Treg therapies cell for autoimmune.
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 4, 2021 | Series B | $265M | 2 | — | — | Detail |
Sep 30, 2020 | Series A | $30M | 3 | — | — | Detail |
Feb 6, 2020 | Series A | $40M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
ARCH Venture Partners | — | Series B |
Lilly Asia Ventures | — | Series B |
Lyell Immunopharma | — | Series A |